AIM: To investigate the impact of genetic polymorphisms in CYP2D6, CYP3A5, CYP2C9 and CYP2C19 on the pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients. METHODS: A total of 165 Asian breast cancer patients receiving 20 mg tamoxifen daily and 228 healthy Asian subjects (Chinese, Malay and Indian; n= 76 each) were recruited. The steady-state plasma concentrations of tamoxifen and its metabolites were quantified using high-performance liquid chromatography. The CYP2D6 polymorphisms were genotyped using the INFINITI™ CYP450 2D6I assay, while the polymorphisms in CYP3A5, CYP2C9 and CYP2C19 were determined via direct sequencing. RESULTS: The polymorphisms, CYP2D6*5 and *10, were significantly associated with lower endoxifen and higher N-desmethyltamoxifen (NDM) concentrations. Patients who were *1/*1 carriers exhibited 2.4- to 2.6-fold higher endoxifen concentrations and 1.9- to 2.1-fold lower NDM concentrations than either *10/*10 or *5/*10 carriers (P < 0.001). Similarly, the endoxifen concentrations were found to be 1.8- to 2.6-times higher in *1/*5 or *1/*10 carriers compared with *10/*10 and *5/*10 carriers (P≤ 0.001). Similar relationships were observed between the CYP2D6 polymorphisms and metabolic ratios of tamoxifen and its metabolites. No significant associations were observed with regards to the polymorphisms in CYP3A5, CYP2C9 and CYP2C19. CONCLUSIONS: The present study in Asian breast cancer patients showed that CYP2D6*5/*10 and *10/*10 genotypes are associated with significantly lower concentrations of the active metabolite of tamoxifen, endoxifen. Identifying such patients before the start of treatment may be useful in optimizing therapy with tamoxifen. The role of CYP3A5, CYP2C9 and CYP2C19 seem to be minor.
AIM: To investigate the impact of genetic polymorphisms in CYP2D6, CYP3A5, CYP2C9 and CYP2C19 on the pharmacokinetics of tamoxifen and its metabolites in Asian breast cancerpatients. METHODS: A total of 165 Asian breast cancerpatients receiving 20 mg tamoxifen daily and 228 healthy Asian subjects (Chinese, Malay and Indian; n= 76 each) were recruited. The steady-state plasma concentrations of tamoxifen and its metabolites were quantified using high-performance liquid chromatography. The CYP2D6 polymorphisms were genotyped using the INFINITI™ CYP450 2D6I assay, while the polymorphisms in CYP3A5, CYP2C9 and CYP2C19 were determined via direct sequencing. RESULTS: The polymorphisms, CYP2D6*5 and *10, were significantly associated with lower endoxifen and higher N-desmethyltamoxifen (NDM) concentrations. Patients who were *1/*1 carriers exhibited 2.4- to 2.6-fold higher endoxifen concentrations and 1.9- to 2.1-fold lower NDM concentrations than either *10/*10 or *5/*10 carriers (P < 0.001). Similarly, the endoxifen concentrations were found to be 1.8- to 2.6-times higher in *1/*5 or *1/*10 carriers compared with *10/*10 and *5/*10 carriers (P≤ 0.001). Similar relationships were observed between the CYP2D6 polymorphisms and metabolic ratios of tamoxifen and its metabolites. No significant associations were observed with regards to the polymorphisms in CYP3A5, CYP2C9 and CYP2C19. CONCLUSIONS: The present study in Asian breast cancerpatients showed that CYP2D6*5/*10 and *10/*10 genotypes are associated with significantly lower concentrations of the active metabolite of tamoxifen, endoxifen. Identifying such patients before the start of treatment may be useful in optimizing therapy with tamoxifen. The role of CYP3A5, CYP2C9 and CYP2C19 seem to be minor.
Authors: P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz Journal: Nat Genet Date: 2001-04 Impact factor: 38.330
Authors: Werner Schroth; Ute Hamann; Peter A Fasching; Silke Dauser; Stefan Winter; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch Journal: Clin Cancer Res Date: 2010-06-01 Impact factor: 12.531
Authors: H Kim Crewe; Lisa M Notley; Rebecca M Wunsch; Martin S Lennard; Elizabeth M J Gillam Journal: Drug Metab Dispos Date: 2002-08 Impact factor: 3.922
Authors: Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart Journal: J Natl Cancer Inst Date: 2003-12-03 Impact factor: 13.506
Authors: Werner Schroth; Matthew P Goetz; Ute Hamann; Peter A Fasching; Marcus Schmidt; Stefan Winter; Peter Fritz; Wolfgang Simon; Vera J Suman; Matthew M Ames; Stephanie L Safgren; Mary J Kuffel; Hans Ulrich Ulmer; Julia Boländer; Reiner Strick; Matthias W Beckmann; Heinz Koelbl; Richard M Weinshilboum; James N Ingle; Michel Eichelbaum; Matthias Schwab; Hiltrud Brauch Journal: JAMA Date: 2009-10-07 Impact factor: 56.272
Authors: Kyung-Hoon Lee; Bryan A Ward; Zeruesenay Desta; David A Flockhart; David R Jones Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2003-07-05 Impact factor: 3.205
Authors: Gilberto Vargas-Alarcón; Julián Ramírez-Bello; Aurora de la Peña; Beatriz Calderón-Cruz; Marco Antonio Peña-Duque; Marco Antonio Martínez-Ríos; Silvestre Ramírez-Fuentes; Oscar Pérez-Méndez; José Manuel Fragoso Journal: Mol Biol Rep Date: 2014-08-09 Impact factor: 2.316
Authors: Thomas P Ahern; Daniel L Hertz; Per Damkier; Bent Ejlertsen; Stephen J Hamilton-Dutoit; James M Rae; Meredith M Regan; Alastair M Thompson; Timothy L Lash; Deirdre P Cronin-Fenton Journal: Am J Epidemiol Date: 2016-12-17 Impact factor: 4.897
Authors: L K Teh; N I Mohamed; M Z Salleh; M Rohaizak; N S Shahrun; J J Saladina; J K S Shia; H Roslan; S Sood; T S Rajoo; S P Muniandy; G Henry; H A Ngow; K T Hla U; J Din Journal: AAPS J Date: 2011-12-20 Impact factor: 4.009
Authors: Thomas P Ahern; Lindsay J Collin; James W Baurley; Anders Kjærsgaard; Rebecca Nash; Maret L Maliniak; Per Damkier; Michael E Zwick; R Benjamin Isett; Peer M Christiansen; Bent Ejlertsen; Kristina L Lauridsen; Kristina B Christensen; Rebecca A Silliman; Henrik Toft Sørensen; Trine Tramm; Stephen Hamilton-Dutoit; Timothy L Lash; Deirdre Cronin-Fenton Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-01-13 Impact factor: 4.254